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Abstract: The androgen receptor (AR) is a pivotal target for the treatment of prostate cancer (PC)
even when the disease progresses toward androgen-independent or castration-resistant forms. In
this study, a series of 15 bicalutamide analogues (sulfide, deshydroxy, sulfone, and O-acetylated)
were prepared and their antiproliferative activity evaluated against four different human prostate
cancer cell lines (22Rv1, DU-145, LNCaP, and VCap). Bicalutamide and enzalutamide were used
as positive controls. Seven of these compounds displayed remarkable enhancement in anticancer
activity across the four PC cell lines. The deshydroxy analogue (16) was the most active compound
with IC50 = 6.59–10.86 µM. Molecular modeling offers a plausible explanation of the higher activity
of the sulfide analogues compared to their sulfone counterparts.
Keywords: androgen receptor (AR); prostate cancer (PC); sulfone; diarylpropionamide; bicalutamide
1. Introduction
The androgen receptor (AR) has essential anabolic and reproductive roles in men
and women. Additionally, AR signaling plays a crucial function in tumorigenesis and
metastasis of different cancer types, including prostate, bladder, kidney, lung, breast, and
liver [1–3]. AR is a member of the nuclear receptor family and consists of three main
functional domains: a variable N-terminal domain, a highly conserved DNA-binding
domain (DBD), and a conserved ligand-binding domain (LBD) [4]. Binding of testos-
terone and dihydrotestosterone (DHT) to the LBD induces AR conformational changes
then translocation into the nucleus to interact with DNA and modulate prostate-specific
antigen (PSA) levels [5]. AR antagonists (antiandrogens) inhibit these processes and are
used for the treatment of advanced prostate cancer (PC) [6,7]. A variety of nonsteroidal
antiandrogens (NSAA) are approved for the treatment of PC. The first generation NSAAs
include flutamide, hydroxyflutamide, and bicalutamide (Figure 1). However, these antian-
drogens eventually fail to inhibit the AR upon long-term treatment, switching from being
AR antagonists to AR agonists with the development of castration-resistant prostate cancer
(CRPC), an aggressive form of the disease with poor prognosis. Similarly, resistance to the
more recent second-generation antiandrogens (enzalutamide, apalutamide) is developing
in PC patients via the upregulation of AR expression [8]. More recently, darolutamide
(ODM-201) has been recently approved and clinically used in patients with nonmetastatic
CRPC [9]. New AR antagonists are continuously needed to improve the efficacy of the
clinically used compounds.
In this paper, we present the design and synthesis of a series of new bicalutamide
analogues, building on our previous work [10–13] to offer new therapeutic options for
combating the resistance observed in the clinical use of AR antagonists.
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Figure 1. Chemical structures of the nonsteroidal antiandrogens (NSAA); flutamide, hy-
droxyflutamide, nilutamide, bicalutamide, enzalutamide, apalutamide, and darolutamide. 
2. Results and Discussion 
Generally, minor chemical changes in the chemical structure of nonsteroidal AR lig-
ands can result in major pharmacological outcomes [14,15]. Previously, we published ex-
tensive SAR studies on bicalutamide analogues [10–13]. Introduction of fluorinated 
groups into the chemical structure of molecules provides a combination of electrostatic, 
steric and lipophilic impacts on the physicochemical properties and biological activities 
[16–18]. 
Here we are exploring the impact of additional chemical structure modifications on the 
antiproliferative activity in prostate cancer cell lines. The three main areas of modification 
are ring A, ring B, and linker area C as illustrated in Figure 2. Fifteen bicalutamide deriv-
atives were prepared and their antiproliferative activity was evaluated in vitro against 
four different human prostate cancer cell lines (22Rv1, DU-145, LNCaP, and VCap). 
 
Figure 2. Chemical structure of bicalutamide and the areas of structural modifications, ring A, ring 
B, and the linker area C. 
2.1. Sulfide Analogues of Bicalutamide 
Phenylacrylamides (4 and 5) were prepared by reacting the corresponding aniline (1 
or 2) with methacryloyl chloride (3) in dimethylacetamide (DMA) [19]. Phenylacrylamides 
(4, 5) were epoxidized by hydrogen peroxide and trifluoroacetic anhydride (TFAA) in di-
chloromethane to give (6 and 7) [20]. Subsequently, the epoxides were reacted with the 
aromatic thiols (8 and 9) to afford the sulfide derivatives (10–12) as racemic mixtures, as 
outlined in Scheme 1.  
i re . i l tr t r s of the nonsteroidal antiandrogens (NS A); flutamide, hydroxyflu-
tamide, nilutamide, bicalutamide, enzalutamide, apalutamide, and darolutamide.
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ligands can result in major pharmacological outcomes [14,15]. Previously, e published ex-
tensive SAR studies on bicalutamide analogues [10–13]. Introduction of fluorinated groups
into the chemical structure of molecules provides a combination of electrostatic, steric and
lipophilic impacts on the physicochemical properties and biological activities [16–18].
Here we are exploring the impact of additional chemical structure modifications
on the antiproliferative activity in prostate cancer cell lines. The three main areas of
modification are ring A, ring B, and linker area C as illustrated in Figure 2. Fifteen
bicalutamide derivatives were prepared and their antiproliferative activity was evaluated
in vitro against four different human prostate cancer cell lines (22Rv1, DU-145, LNCaP, and
VCap).
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2.1. Sulfide Analogues of Bicalutamide
Phenylacrylamides (4 and 5) were prepared by reacting the corresponding aniline (1
or 2) with methacryloyl chloride (3) in dimethylacetamide (DMA) [19]. Phenylacrylamides
(4, 5) were epoxidized by hydrogen peroxide and trifluoroacetic anhydride (TFAA) in
dichloromethane to give (6 and 7) [20]. Subsequently, the epoxides were reacted with the
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Scheme 1. Reagents and conditions, (i) DMA, rt, 3 h; (ii) H2O2, TFAA, DCM, rt, 24 h; (iii) NaH, THF, RT, 24 h. 
The sulfide bicalutamide derivatives (10–12) were evaluated for their antiprolifera-
tive activity in vitro against four human prostate cancer cell lines (22Rv1, DU-145, LNCaP, 
and VCap) using the Oncotest monolayer assay (see Experimental Section). Bicalutamide 
and enzalutamide were used as positive controls. Compound 12 showed approximately 
twofold activity improvement in three cell lines, 22Rv1, LNCaP, and VCap (IC50 = 
16.88−27.30 µM), compared to bicalutamide. Meanwhile, compound 10 displayed en-
hanced activity (IC50 = 23.51–27.94 µM) in 22Rv1 and LNCaP, whereas compound 11 was 
inactive (> 100 µM) in all cell lines except LNCaP (IC50 = 16.34 µM) (Table 1). 
Table 1. In vitro antiproliferative activity of the sulfide analogues of bicalutamide (10–12) across 
four human prostate cancer cell lines (DU-145, 22Rv, LNCaP, and VCap). All data are mean values 
from experiments carried out on three separate occasions. 
ID 
22Rv1 
IC50 (µM) 
DU-145 
IC50 (µM) 
LNCaP 
IC50 (µM) 
VCap 
IC50 (µM) 
10 27.94 40.47 23.51 51.61 
11 >100 >100 16.34 >100 
12 17.42 43.54 16.88 27.30 
Bicalutamide 46.25  45.41 45.20  51.61  
Enzalutamide 31.76 32.27 11.47 53.04 
2.2. Deshydroxy Sulfide Analogues of Bicalutamide 
Reacting 4-nitro-2-(trifluoromethyl) aniline (2) with methacryloyl chloride (3) in di-
methylacetamide (DMA) generated phenylacrylamide derivative (5) [16], which was sub-
sequently reacted with the appropriate thiols (13–15) to afford the corresponding 
deshydroxy sulfide derivatives (16–18) as racemic mixtures, as described in Scheme 2. 
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activity improvement in three cell lines, 22Rv1, LNCaP, and VCap (IC50 = 16.88−27.30 µM),
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23.51–27.94 µM) in 22Rv1 and LNCaP, whereas compound 11 was inactive (> 100 µM) in
all cell lines except LNCaP (IC50 = 16.34 µM) (Table 1).
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Scheme 2. Reagents and conditions, (i) DMA, rt, 3 h; (ii) NaH, THF, RT, 24 h. 
The deshydroxy sulfide bicalutamide derivatives (16–18) were assessed for their an-
tiproliferative activity in four human prostate cancer cell lines (22Rv1, DU-145, LNCaP, 
and VCap). Compound 16 displayed approximately 7-fold enhanced activity (IC50 = 6.59 
µM) in 22Rv1 and 4- to 5-fold enhanced activity (IC50 = 8.22−10.86 µM) in DU-145, LNCaP, 
and VCap, compared to bicalutamide. Similarly, compound 17 showed activity improve-
ment in all cell lines (IC50 = 9.99−30.85 µM). However, compound 18 showed loss of activity 
(> 100 µM) in three cell lines: 22Rv1, DU-145, and VCap, Table 2. 
Table 2. In vitro antiproliferative activity of the deshydroxy sulfide analogues of bicalutamide 
(16–18) across four human prostate cancer cell lines (DU-145, 22Rv, LNCaP, and VCap). All data 
are mean values from experiments carried out on three separate occasions. 
ID 
22Rv1 
IC50 (µM) 
DU-145 
IC50 (µM) 
LNCaP 
IC50 (µM) 
VCap 
IC50 (µM) 
16 6.59 8.22 9.44 10.86 
17 17.36 20.34 9.99 30.85 
18 >100 >100 83.34 >100 
Bicalutamide 46.25  45.41 45.20  51.61  
Enzalutamide 31.76 32.27 11.47 53.04 
2.3. Sulfone Analogues of Bicalutamide 
Bicalutamide sulfone (SO2) derivatives (19–22) were prepared by oxidation of the cor-
responding sulfide derivatives using two equivalents of m-chloroperbenzoic acid 
(mCPBA) over a reaction time of 24 h at room temperature, resulting in the complete oxi-
dation into sulfone analogues [19], as outlined in Scheme 3. 
 
Scheme 3. Reagents and conditions, (i) mCPBA (2 equiv), DCM, rt, 24 h. 
Evaluation of the antiproliferative activity of the sulfone compounds showed that 
compounds 21 and 22 retained good activity in the four human prostate cancer cell lines 
(22Rv1, DU-145, LNCaP, and VCap) but to a lesser extent compared to their correspond-
ing thioether analogues 16 and 17, respectively, Figure 3. On the other hand, compounds 
19 and 20 did not show any activity up to 100 µM, Table 3. 
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6.59 µM) in 22Rv1 and 4- to 5-fold enhanced activity (IC50 = 8.22−10.86 µM) in DU-145,
LNCaP, and VCap, compared to bicalutamide. Similarly, compound 17 showed activity
improvement in all cell lines (IC50 = 9.99−30.85 µM). However, compound 18 showed loss
of activity (> 100 µM) in three cell lines: 22Rv1, DU-145, and VCap, Table 2.
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thioether analogues 16 and 17, respectively, Figure 3. On the other hand, compounds 19
and 20 did not show any activity up to 100 µM, Table 3.
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Figure 3. Dose response curves of sulfide compounds 16 (A) and 17 (C) compared to their corresponding sulfone deriva-
tives 21 (B) and 22 (D), respectively, in the Oncotest monolayer assay of 22Rv1 (red), DU-145 (green), LnCaP (blue), and 
VCap (yellow) cell lines. 
An in silico docking study was performed to compare the putative binding modes of 
the sulfide (S) compound 16 (IC50 = 6.59–10.86 µM) and its sulfone (SO2) analogue 21 (IC50 
= 24.64–43.04 µM). Both compounds share key interactions including an H-bond between 
the nitro group (NO2) and the guanidine group of Arg 752 of helix 5. Another H-bond was 
observed between the amide (NH) and the side chain S-methyl thioether (SCH3) group of 
Met 742 amino acid residue. However, only compound 16 shows an H-bond between its 
nitro group (NO2) and the side chain amide (NH2) group of Gln 711 (Figure 4A), which 
may explain its higher activity compared to its sulfone analogue (21) which lacks such 
interaction (Figure 4B). In addition, hydrophobic interactions were observed between the 
4-trifluoromethyl phenyl moiety and the surrounding hydrophobic pocket formed of res-
idues, Trp 741, Met 745, Leu 712, and Met 787 in both compounds, Figure 4. 
Figure 3. Dose response curves of sulfide compounds 16 (A) and 17 (C) compared to their corresponding sulfone derivatives
21 (B) and 22 (D), respectively, in the Oncotest monolayer assay of 22Rv1 (red), DU-145 (green), LnCaP (blue), and VCap
(yellow) cell lines.
Table 3. In vitro antiproliferative activity of the sulfone analogues (19–22) across four human prostate
cancer cell lines (DU-145, 22Rv, LNCaP, and VCap). All data are mean values from experiments
carried out on three separate occasions.
ID 22Rv1IC50 (µM)
DU-145
IC50 (µM)
LNCaP
IC50 (µM)
VCap
IC50 (µM)
19 >100 >100 >100 >100
20 >100 >100 >100 >100
21 24.64 32.89 30.59 43.04
22 36.42 39.91 20.49 >100
Bicalutamide 46.25 45.41 45.20 51.61
Enzalutamide 31.76 32.27 11.47 53.04
An in silico docking study was performed to compare the putative binding modes of
the sulfide (S) compound 16 (IC50 = 6.59–10.86 µM) and its sulfone (SO2) analogue 21 (IC50
= 24.64–43.04 µM). Both compounds share key interactions including an H-bond between
the nitro group (NO2) and the guanidine group of Arg 752 of helix 5. Another H-bond was
observed between the amide (NH) and the side chain S-methyl thioether (SCH3) group of
Met 742 amino acid residue. However, only compound 16 shows an H-bond between its
nitro group (NO2) and the side chain amide (NH2) group of Gln 711 (Figure 4A), which
may explain its higher activity compared to its sulfone analogue (21) which lacks such
interaction (Figure 4B). In addition, hydrophobic interactions were observed between
Molecules 2021, 26, 56 6 of 14
the 4-trifluoromethyl phenyl moiety and the surrounding hydrophobic pocket formed of
residues, Trp 741, Met 745, Leu 712, and Met 787 in both compounds, Figure 4.Molecules 2021, 26, x FOR PEER REVIEW 6 of 14 
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Figure 4. The predicted binding mode of compounds 16 (A) and 21 (B) within the hAR-LBD showing H-bond interactions 
(blue dashed line) with Arg 752, Gln 711, Met 742. 
2.4. O-Acetylated Analogues of Bicalutamide 
The acetyl derivatives (27, 28) were prepared according to the route outlined in 
Scheme 4. The 4-trifluoromethyl thiophenol (13) was reacted with methyl 2-methylglyci-
date (23) followed by saponification using sodium hydroxide solution to form propionic 
acid derivative (24), which was then acetylated using acetic anhydride to afford (25). Cou-
pling with aniline derivatives (2, 26) was achieved using dimethylaminopyridine (DMAP) 
to afford 27 and 28 [21]. Sulfoxide derivatives (29 and 30) were prepared from 27 and 28, 
respectively, using one equivalent of mCPBA at 0 °C for 15–30 min while the sulfone de-
rivative (31) was prepared from 27 using two equivalents of mCPBA at room temperature 
for 24 h. 
  
Scheme 4. Reagents and conditions, (i) MeONa/MeOH, toluene, 60 °C, 3 h, then NaOH 10%; (ii) Ac2O, toluene, rt, 24 h; 
(iii) SOCl2, DMAP, toluene; (iv) mCPBA (1 equiv), DCM, 0 °C, 15–30 min; (v) mCPBA (2 equiv), DCM, rt, 24 h. 
The antiproliferative activity of derivatives (27–31) showed that compound 27 dis-
played the most potent activity (IC50 = 4.69–15.03 µM) across the four human prostate can-
cer cell lines (22Rv1, DU-145, LNCaP, and VCap). Compounds 28 and 30 retained good 
activity, comparable (28) and better (30) than bicalutamide. However, compounds 29 and 
31 did not possess antiproliferative activity (>100 µM), Table 4. 
  
.
li ) it , l , et 742.
2.4. O-Acetylated Analogues of Bicalutamide
The acetyl derivatives (27, 28) were prepared according to the route outlined in
Scheme 4. The 4-trifluoromethyl thiophenol (13) was reacted with methyl 2-methylglycidate
(23) followed by saponification using sodium hydroxide solution to form propionic acid
derivative (24), which was then acetylated using acetic anhydride to afford (25). Coupling
with aniline derivatives (2, 26) was achieved using dimethylaminopyridine (DMAP) to
afford 27 and 28 [21]. Sulfoxide derivatives (29 and 30) were prepared from 27 and 28,
respectively, using one equivalent of mCPBA at 0 ◦C for 15–30 min while the sulfone
derivative (31) was prepared from 27 using two equivalents of mCPBA at room temperature
for 24 h.
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activity, comparable (28) and better (30) than bicalutamide. However, compounds 29 and 
31 did not possess antiproliferative activity (>100 µM), Table 4. 
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Table 4. In vitro antiproliferative activity of bicalutamide analogues (27–31) across four human
prostate cancer cell lines (DU-145, 22Rv, LNCaP, and VCap). All data are mean values from experi-
ments carried out on three separate occasions.
ID
Structure
22Rv1
IC50 (µM)
DU-145
IC50 (µM)
LNCaP
IC50 (µM)
VCap
IC50 (µM)
27 7.74 15.03 4.69 8.09
28 41.06 59.79 75.61 51.87
29 >100 >100 >100 >100
30 26.71 34.73 24.01 32.30
31 >100 >100 >100 >100
Bicalutamide 46.25 45.41 45.20 51.61
Enzalutamide 31.76 32.27 11.47 53.04
The predicted docking mode of compound 27 within the hAR-LBD showed H-bond
interactions between the nitro group (NO2) and the guanidine group of Arg 752. In addition,
hydrophobic interactions were observed between the 4-trifluoromethyl phenyl moiety and
the surrounding hydrophobic pocket, π-π stacking between the terminal phenyl ring and
the indole side chain of Trp 741. Also, the acetyl moiety of compound 27 seemed to occupy
a small hydrophobic subpocket, Figure 5A. The binding mode of bicalutamide is shown in
Figure 5B.
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3. Materials and Methods
3.1. Chemistry
All chemicals were purchased from Sigma-Aldrich or Alfa Aesar and were used
without further purification. Thin-layer chromatography (TLC): precoated aluminum-
backed plates (60 F254, 0.2 mm thickness, Merck) were visualized under both short- and
long-wave UV light (254 and 366 nm, respectively). Flash column chromatography was
carried out using silica gel supplied by Fisher (60A, 35–70 mm); 1H-NMR (500 MHz),
13C-NMR (125 MHz), and 19F-NMR (470 MHz) spectra were recorded on a Bruker Avance
500 MHz spectrometer at 25 ◦C. Chemical shifts (δ) are expressed in parts per illion (pp )
and coupling constants (J) are given in hertz ( z). The follo ing abbreviations are used
in the assign ent of signals: s (singlet), bs (broa singlet), d (doublet), t (triplet), q
( artet), ( i tet), ( lti let), ( let f o blet), dt (doublet of triplet), td
(triple oublet), dq (double q artet), ( ultiplet), d (double ultiplet). everse-phase
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HPLC, eluting with H2O/CH3CN from 90/10 to 0/100 in 30 min; flow = 1 mL/min,
tR = 20.39 min.
3.1.1. General Method for the Preparation of Intermediates 4–5
Methacryloyl chloride 3 (8.4 mL, 85.96 mmol) was added over the course of 10 min
to a stirring solution of the appropriate trifluoromethylaniline 1–2 (10.75 mmol) in N,N-
dimethylacetamide (10 mL) at room temperature for 24 h. After the reaction was complete,
the mixture was diluted with ethyl acetate (100 mL) and extracted with saturated NaHCO3
solution (2 × 50 mL), then cold brine (2 × 50 mL). The combined organic layer was dried
over anhydrous Na2SO4 and the solvent was removed under reduced pressure. The crude
oil residue was purified by flash column chromatography eluting with chloroform-ethyl
acetate 95:5 v/v to obtain the titled compounds.
N-(4-cyano-3-(trifluoromethyl)phenyl)methacrylamide (4) [22], Yield 92%, 1H-NMR (CDCl3) δ
8.10 (d, J = 2Hz, 1H, ArH), 8.06 (bs, 1H, NH), 8.01 (dd, J = 2, 8.5 Hz, 1H, ArH), 7.81 (d, J =
8.5Hz, 1H, ArH), 5.89 (d, J = 1Hz, 1H, CH2), 5.62 (q, J = 1.5Hz, 1H, CH2), 2.10 (dd, J = 0.5,
1.5 Hz, 3H, CH3). 19F-NMR: (CDCl3) δ −62.23.
N-(4-Nitro-2-(trifluoromethyl)phenyl)methacrylamide (5) [22], Yield 94%, 1H-NMR (CDCl3) δ
8.73 (d, J = 9 Hz, 1H, ArH), 8.46 (d, J = 3 Hz, 1H, ArH), 8.37 (dd, J = 9 Hz, 2.5 Hz, 1H, ArH),
8.17 (bs, 1H, NH), 5.85 (q, J= 0.5 Hz, 1H, CH2), 5.58 (q, J = 1.5 Hz, 1H, CH2), 2.15-2.13 (dd, J
= 1, 1.5 Hz, 1H, CH3). 19F-NMR: (CDCl3) d-61.31.
3.1.2. General Method for the Preparation of Intermediates 6–7
To a stirred solution of the intermediate 4–5 (3 mmol) in DCM (7 mL) was added 30%
hydrogen peroxide (3.6 mL, 32.03 mmol). The reaction mixture was put in a water bath at rt
and trifluoroacetic anhydride (3.7 mL, 26.7 mmol) was added slowly to the mixture, which
was then stirred for 24 h. The reaction mixture was transferred to a separating funnel using
DCM (30 mL). The organic layer was washed with distilled water (20 mL), sat. aq. Na2S2O3
(4 × 20 mL), sat. aq. NaHCO3 (3 × 20 mL), and brine (20 mL), dried over Na2SO4, and
concentrated at reduced pressure.
N-(4-Cyano-3-(trifluoromethyl)phenyl)-2-methyloxirane-2-carboxamide (6) [22].The data are in
accordance with literature data. Obtained in 86% yield as a yellow solid. 1H-NMR (CDCl3):
d 8.38 (bs, 1H), 8.00 (d, J = 2.1 Hz, 1H), 7.88 (dd, J = 8.5 Hz, 2.1 Hz, 1H), 7.78 (d, J = 8.5 Hz,
1H), 3.00 (s, 2H), 1.68 (s, 3H).
2-Methyl-N-(4-nitro-2-(trifluoromethyl)phenyl)oxirane-2-carboxamide (7). Obtained in 71%
yield as a yellow wax. 1H-NMR (CDCl3): d 8.92 (bs, 1H), 8.74 (d, J = 9.6 Hz, 1H), 8.53 (d, J =
2.5 Hz, 1H), 8.44 (dd, J = 9.6 Hz, 2.5 Hz, 1H), 3.04 (d, J= 4.6 Hz, 1H), 3.02 (d, J = 4.6 Hz, 1H),
1.72 (s, 3H). 19F-NMR (CDCl3): d −61.69 (s, 3F). 13C-NMR (CDCl3): d 169.2, 142.9, 140.4,
128.35 (m), 123.7, 122.3 (m), 121.6, 119.2 (m), 56.5, 53.9, 16.4.
3.1.3. General Method for the Preparation of Compounds 10–12, 22–29
To a mixture of sodium hydride (NaH) (60% in mineral oil, 0.050 g, 1.23 mmol) in
anhydrous THF (2 mL) at 0 ◦C under Ar atmosphere was added a solution of the differently
substituted thiophenol 8, 9, 19–21 (1.11 mmol) in 1 mL of anhydrous THF. This mixture
was stirred at rt for 20 min. A solution of the different intermediate 17–21 (0.74 mmol)
in anhydrous THF (3 mL) was added slowly. The reaction mixture was stirred at rt for
24h.The mixture was then diluted with ethyl acetate (30 mL), washed with brine (15 mL)
and water (30 mL), dried over Na2SO4, and concentrated under vacuum. The crude residue
was purified by flash column chromatography.
N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methyl-3-(pyridin-2-ylthio) propanamide (10),
yield 79%, 1H-NMR (CDCl3) δ 9.64 (s, 1H, NH), 8.89 (s, 1H, ArH), 8.39 (ddd, J = 1, 1.5, 5
Hz, 1H, ArH), 8.13 (d, J = 2 Hz, 1H, ArH), 8.00 (dd, J = 2, 8.5 Hz, 1H, ArH), 7.91 (d, J = 8.5
Hz, 1H, ArH), 7.61 (ddd, J = 2, 8, 8.5 Hz, 1H, ArH), 7.37 (dt, J = 1, 8 Hz, 1H, ArH), 7.17
(ddd, J = 1, 5, 7.5 Hz, 1H, ArH), 3.61 (d, J = 15.5 Hz, 1H, CH2), 3.50 (d, J = 15 Hz, 1H, CH2),
1.63 (s, 3H, CH3); 19F-NMR (CDCl3) δ −62.16 (s, 3F); 13C-NMR (CDCl3) δ 175.18 (C=O),
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158.85 (ArC), 148.32 (ArCH), 141.69 (ArC), 137.45 (ArCH), 135.80 (ArCH), 133.92 (q, 2JC-F
= 32.5 Hz, ArC), 123.55 (ArCH), 122.19 (q, 1JC-F = 271.3 Hz, CF3), 121.66 (ArCH), 120.92
(ArCH), 117.16 (q, 3JC-F = 5 Hz, ArCH), 115.67 (ArC), 104.15 (CN), 77.01 (COH), 41.48 (CH2),
26.81 (CH3). MS [ESI, m/z]: 382.1 [M+H]+, 404.1 [M+Na]+. Reverse-phase HPLC, eluting
with H2O/CH3CN from 90/10 to 0/100 in 30 min; flow = 1 mL/min, tR = 21.17 min 99.5%.
2-Hydroxy-2-methyl-N-(4-nitro-2-(trifluoromethyl)phenyl)-3-(pyridin-2-ylthio) propenamide (11),
yield 75%, 1H-NMR (CDCl3) δ 10.26 (s, 1H, NH), 9.08 (s, 1H, ArH), 8.84 (d, J = 9 Hz, 1H,
ArH), 8.52 (d, J = 3 Hz, 1H, ArH), 8.42 (m, 2H, ArH), 7.61 (m, 1H, ArH), 7.37 (d, J = 8.5 Hz,
1H, ArH), 7.18 (m, 1H, ArH), 3.60 (d, J = 15 Hz, 1H, CH2), 3.52 (d, J = 15 Hz, 1H, CH2),
1.65 (s, 3H, CH3); 19F-NMR (CDCl3) δ −62.01 (s, 3F); 13C-NMR (CDCl3) δ 175.24 (C=O),
158.68 (ArC), 148.31 (ArCH), 142.62 (ArC), 141.00 (ArC), 137.40 (ArCH), 128.27 (ArCH),
123.36 (ArCH), 122.78 (q, 1JC-F = 272 Hz, CF3), 122.36 (q, 3JC-F = 5.5 Hz, ArCH), 122.04
(ArCH), 120.86 (ArCH), 119.28 (q, 2JC-F = 32.5 Hz, ArC), 77.13 (COH), 41.46 (CH2), 26.54
(CH3). MS (ES+) m/z: 402.1 [M + H]+ 424.1 [M + Na]+. Reverse-phase HPLC, eluting with
H2O/CH3CN from 90/10 to 0/100 in 30 min; flow = 1 mL/min, tR = 23.98 min 99.75%.
2-Hydroxy-2-methyl-N-(4-nitro-2-(trifluoromethyl)phenyl)-3-(4-(trifluoromethyl) pyrimidin-2-
ylthio)propanamide (12), yield 73%, 1H-NMR (CDCl3) δ 10.02 (s, 1H, NH), 8.83 (d, J =
5 Hz, 1H, ArH), 8.80 (d, J = 9.5 Hz, 1H, ArH), 8.53 (d, J = 2.5 Hz, 1H, ArH), 8.45 (dd, J = 2.5,
9 Hz, 1H, ArH), 7.46 (d, J = 5 Hz, 1H, ArH), 6.43 (s, 1H, OH), 3.69 (s, 2H, CH2), 1.68 (s, 3H,
CH3); 19F-NMR (CDCl3) δ −62.00, -70.26; 13C-NMR (CDCl3) δ 174.21 (ArC), 173.91 (C=O),
159.79 (ArCH), 156.02 (q, 2JC-F = 36.3 Hz, ArC), 142.87 (ArC), 140.67 (ArC), 128.31 (ArCH),
122.76 (q, 1JC-F = 271.9 Hz, CF3), 122.39 (q, 3JC-F = 5.5 Hz, ArCH), 122.30 (ArCH), 119.79
(q, 1JC-F = 274 Hz, CF3), 119.49 (q, 2JC-F = 31.6 Hz, ArC), 112.97 (q, 3JC-F = 2.6 Hz, ArCH),
77.82 (COH), 40.67 (CH2), 26.38 (CH3).MS (ES+) m/z: 471.1 [M + H]+, 493.1 [M + Na]+.
tR = 23.16 min 95.22%.
3.1.4. General Method for the Preparation of Compounds 16–18
To a mixture of 60% sodium hydride (NaH) in mineral oil (2.36 mmol) in 5 mL of
anhydrous tetrahydrofuran at 0 ◦C under anhydrous THF under nitrogen atmosphere
was added dropwise the corresponding thiophenol 10–13 (2.05 mmol). This mixture was
stirred at room temperature for 20 min. A solution of the intermediate 5 (1.57 mmol in 5
mL anhydrous tetrahydrofuran) was added slowly to the thiophenol mixture and stirred
at room temperature for 24h. The mixture was concentrated under vacuum, then diluted
with 30 mL ethyl acetate washed with 20 mL brine and 30 mL water, dried over anhydrous
sodium sulfate, and concentrated under vacuum. The crude residue was purified by
column chromatography eluting with chloroform-ethyl acetate gradually increasing from
95:5 to 90:10 v/v [12].
2-Methyl-N-(4-nitro-2-(trifluoromethyl) phenyl)-3-(4-(trifluoromethyl)phenylthio) propanamide
(16), yield 71%, 1H-NMR (CDCl3) δ 8.64 (d, J = 9 Hz, 1H, ArH), 8.54 (d, J = 3 Hz, 1H,
ArH), 8.42 (dd, J = 3, 9.5 Hz, 1H, ArH), 7.80 (s, 1H, OH), 7.55 (d, J = 8 Hz, 2H, ArH), 7.44
(d, J = 8 Hz, 2H, ArH), 3.43 (dd, J = 8.5, 14 Hz, 1H, CH2), 3.16 (dd, J = 5.5, 13.5 Hz, 1H,
CH2), 2.73 (m, 1H, CH), 1.44 (d, J = 7 Hz, 3H, CH3); 19F-NMR (CDCl3) δ: −62.63, −61.00;
13C-NMR (CDCl3) δ: 172.73 (C=O), 143.04 (ArC), 141.71 (ArC), 140.56 (ArC), 128.49 (ArCH),
128.26 (ArCH), 128.02 (m, ArC), 125.93 (q, 3JC-F = 3.7 Hz, ArCH), 125.87, 123.30 (ArCH),
123.73 (m, 2CF3), 122.31 (q, 3JC-F = 5 Hz, ArCH), 120.65 (m, ArC), 43.09 (CH), 36.32 (CH2),
17.46 (CH3). MS (ES+) m/z: 453.1 [M + H]+, 475.1 [M + Na]+. Reverse-phase HPLC, eluting
with H2O/CH3CN from 90/10 to 0/100 in 30 min; flow = 1 mL/min, tR = 24.45 min 98.0%.
2-Methyl-N-(4-nitro-2-(trifluoromethyl)phenyl)-3-(2-(trifluoromethoxy)phenylthio) propanamide
(17), yield 69%, 1H-NMR (CDCl3) δ 8.65 (d, J = 9.5 Hz, 1H, ArH), 8.54 (d, J = 2.5 Hz, 1H,
ArH), 8.43 (dd, J = 3, 9.5 Hz, 1H, ArH), 7.80 (s, 1H, NH), 7.48 (m, 1H, ArH), 7.23 (m, 3H,
ArH), 3.37 (dd, J = 8, 13.5 Hz, 1H, CH2), 3.08 (dd, J = 5.5, 13.5 Hz, 1H, CH2), 2.68 (m, 1H,
CH), 1.42 (d, J = 7 Hz 3H, CH3); 19F-NMR (CDCl3) δ −61.13, −57.29; 13C-NMR (CDCl3)
δ 172.90 (C=O), 160.91 (ArC), 143.04 (ArC), 140.30 (ArC), 133.91 (ArCH), 131.48 (ArCH),
129.45 (m, CF3), 128.22 (ArCH), 127.36 (ArCH), 123.96 (m, CF3), 123.48 (ArCH), 122.30 (q,
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3JC-F = 5 Hz, ArCH), 121.55 (m, ArC), 121.25 (ArCH), 120.58 (ArC), 43.12 (CH), 36.58 (CH2),
17.37 (CH3).MS (ES+) m/z: 469.1 [M + H]+, 491.1 [M + Na]+. tR = 24.22 min 95.02%.
3-(2,4-Difluorophenylthio)-2-methyl-N-(4-nitro-2-(trifluoromethyl)phenyl) propanamide (18), yield
75%, 1H-NMR (CDCl3) δ 8.68 (d, J = 9.5 Hz, 1H, ArH), 8.55 (d, J = 2.5 Hz, 1H, ArH), 8.44
(dd, J = 2.5, 9 Hz, 1H, ArH), 7.85 (s, 1H, NH), 7.47 (m, 1H, ArH), 6.88 (m, 2H, ArH), 3.27
(dd, J = 8.5, 14 Hz, 1H, CH2), 2.99 (dd, J = 5.5, 14 Hz, 1H, CH2), 2.64 (m, 1H, CH), 1.38 (d, J
= 7 Hz, 3H, CH3); 19F-NMR (CDCl3) δ −61.06 (3F), −102.93 (1F), −108.49 (1F); 13C-NMR
(CDCl3) δ 172.98 (C=O), 164.15 (ArC), 158.55 (ArC), 142.99 (ArC), 140.77 (ArC), 135.81 (m,
ArCH), 135.73, 128.25 (ArCH), 124.89 (q, 1JC-F = 228 Hz, ArC), 123.99 (ArC), 123.29 (ArCH),
122.29 (q, 3JC-F = 6.3 Hz, ArCH), 121.87 (m, ArC), 112.14 (dd, 4JC-F = 3.6 Hz, 2JC-F = 22.5 Hz,
ArCH), 104.82 (t, 2JC-F = 25.9 Hz, ArCH), 43.54 (CH), 38.28 (CH2), 17.38 (CH3). MS (ES+)
m/z: 421.1 [M + H]+, 443.1 [M + Na]+. Reverse-phase HPLC, eluting with H2O/CH3CN
from 90/10 to 0/100 in 30 min; flow = 1 mL/min, tR = 24.92 min 95.10%.
3.1.5. General Method for the Preparation of Sulfone Compounds 19–22, 31
To a stirring solution of the different sulfide 10, 11, 16, 17, 27 (0.7 mmol) in 5 mL
anhydrous dichloromethane (DCM) was added m-chloroperbenzoic acid (mCPBA) (1.4
mmol). The solution was stirred at room temperature for 24 h. The reaction mixture was
neutralized with 1M sodium hydroxide. Distilled water (50 mL) was added to the reaction
mixture and was extracted with 2 × 50 mL of dichloromethane. The combined organic
layers were washed, dried over anhydrous sodium sulfate, and concentrated in vacuo. The
crude residue was purified by column chromatography, preparative TLC, or crystallization
from methanol.
N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methyl-3-(pyridin-2-ylsulfonyl) propanamide
(19), yield 76%, 1H-NMR (CDCl3) δ 9.32 (s, 1H, NH), 8.74 (d, J = 5 Hz, 1H, ArH), 8.13 (d, J =
8 Hz, 1H, ArH), 8.07 (m, 2H, ArH), 7.96 (d, J = 7.5 Hz, 1H, ArH), 7.81 (d, J = 8 Hz, 1H, ArH),
7.68 (m, 1H, ArH), 6.86 (s, 1H, OH), 4.38 (d, J = 15.5 Hz, 1H, CH2), 3.76 (d, J = 15 Hz, 1H,
CH2), 1.64 (s, 3H, CH3); 19F-NMR (CDCl3) δ −62.17; 13C-NMR (CDCl3) δ: 172.72 (C=O),
155.12 (ArC), 149.46 (ArCH), 141.50 (ArC), 139.43 (ArCH), 135.82 (ArCH), 136.55 (m, CF3),
128.21 (ArCH), 121.98 (ArCH), 121.93 (ArCH), 121.42 (ArC), 117.37 (q, 3JC-F = 5 Hz, ArCH),
115.54 (CN), 99.99 (ArC), 73.45 (COH), 60.99 (CH2), 27.77 (CH3). MS (ES+) m/z: 414.1 [M
+ H]+, 436.1 [M + Na]+. Reverse-phase HPLC, eluting with H2O/CH3CN from 90/10 to
0/100 in 30 min; flow = 1 mL/min, tR = 15.42 min 98.7%.
2-Hydroxy-2-methyl-N-(4-nitro-2-(trifluoromethyl)phenyl)-3-(pyridin-2-yl sulfonyl) propanamide,
(20), yield 81%, 1H-NMR (CDCl3) δ 9.88 (s, 1H, NH), 8.77 (d, J = 5 Hz, 1H, ArH), 8.71 (d,
J = 9 Hz, 1H, ArH), 8.55 (d, J = 2.5 Hz, 1H, ArH), 8.44 (dd, J = 3, 9.5 Hz, 1H, ArH), 8.14
(d, J = 7.5 Hz, 1H, ArH), 7.70 (m, 1H, ArH), 8.09 (m, 1H, ArH), 7.09 (s, 1H, OH), 4.39 (d, J
= 15.5 Hz, 1H, CH2), 3.81 (d, J = 15.5 Hz, 1H, CH2), 1.65 (s, 3H, CH3); 19F-NMR (CDCl3)
δ −61.68; 13C-NMR (CDCl3) δ 172.90 (C=O), 157.37 (ArC), 149.35 (ArCH), 142.95 (ArC),
140.82 (ArC), 139.55 (ArCH), 128.25 (ArCH), 123.91 (m, ArC), 123.01 (ArCH), 122.72 (ArCH),
122.38 (m, CF3) 122.34 (q, 3JC-F = 5.6 Hz, ArCH), 121.79 (ArCH), 73.37 (COH), 61.37 (CH2),
27.64 (CH3).MS (ES+) m/z: 434.1 [M + H]+, 456.1 [M + Na]+. tR = 17.44 min 99.47%.
2-Methyl-N-(4-nitro-2-(trifluoromethyl)phenyl)-3-((4-(trifluoromethyl)phenyl) sulfonyl) prope-
namide (21), yield 74.7%, 1H-NMR (CDCl3) δ 8.57 (d, J = 2 Hz, 1H, ArH), 8.46 (d, J = 9 Hz,
1H, ArH), 8.43 (dd, J = 9.5, 2.5 Hz, 1H, ArH), 8.10 (d, J = 8 Hz, 2H, ArH), 7.86 (m, 3H, ArH,
NH), 3.78 (dd, J = 4, 9.5 Hz, 1H, CH2), 3.70 (dd, J = 4.5, 10.5 Hz, 1H, CH2), 3.12 (m, 1H,
CH), 1.39 (d, J = 7.5 Hz, 3H, CH3); 19F-NMR (CDCl3) δ −60.92, −63.33; 13C-NMR (CDCl3)
δ 171.48 (C=O), 150.72 (ArC), 143.42 (ArC), 140.31 (ArC), 135.77, 128.69 (ArCH), 128.21
(ArCH), 126.64 (q, 3JC-F = 3.6 Hz, ArCH), 124.06 (ArCH), 124.74, 124.70, 124.67, 124.47,
124.42, 124.39, 122.40, 122.36 (q, 3JC-F = 5.4 Hz, ArCH), 120.8 (q, 1JC-F = 232.8 Hz, CF3),
120.32, 58.70, 37.14 (CH2), 18.57 (CH3). MS (ES+) m/z: 485.1 [M + H]+, 507.1 [M + Na]+.
Reverse-phase HPLC, eluting with H2O/CH3CN from 90/10 to 0/100 in 30 min; flow = 1
mL/min, tR = 21.79 min 97.30%.
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2-Methyl-N-(4-nitro-2-(trifluoromethyl)phenyl)-3-(2-(trifluoromethoxy) phenylsulfonyl)propanamide
(22), yield 71.6%, 1H-NMR (CDCl3) δ 8.55 (d, J = 2.5 Hz, 1H, ArH), 8.49 (d, J = 9 Hz, 1H,
ArH), 8.42 (dd, J = 2.5, 9 Hz, 1H, ArH), 8.08 (dd, J = 2, 8 Hz, 1H, ArH), 7.88 (s, 1H, NH), 7.73
(ddd, J = 2, 7.5, 8.5 Hz, 1H, ArH), 7.49 (2m, 1H, ArH), 7.45 (td, J = 1, 7.5 Hz, 1H, ArH), 4.01
(dd, J = 8.5, 14 Hz, 1H, CH2), 3.39 (dd, J = 4, 14 Hz, 1H, CH2), 3.12 (m, 1H, CH), 1.48 (d, J =
7.5 Hz, 3H, CH3); 19F-NMR (CDCl3) δ −60.99, −56.24; 13C-NMR (CDCl3) δ 171.28 (C=O),
160.35 (ArC), 143.61 (ArC), 140.61 (ArC), 135.96 (ArCH), 130.98 (ArCH), 129.50 (ArC), 129.16
(ArC), 128.13 (ArCH), 126.79 (ArCH), 123.90 (ArCH), 123.27 (CF3), 121.45 (ArC), 120.26
(ArCH), 120.24 (ArCH), 58.28 (CH2), 37.21 (CH), 18.37 (CH3). MS (ES+) m/z: 501.1 [M + H]+,
523.0 [M + Na]+. Reverse-phase HPLC, eluting with H2O/CH3CN from 90/10 to 0/100 in
30 min; flow = 1 mL/min, tR = 24.22 min 95.00%.
3.1.6. General Method for the Preparation of Acetylated Compounds 27, 28
4-trifluoromethyl thiophenol (13, 0.283 g, 0.0178 moles) was placed in a round-
bottomed flask and heated to 55–60 ◦C.; methyl 2-methylglycidate (23, 2.11 g, 0.0181 moles)
was then added slowly over an hour at 55–60 ◦C after a further 60 min at 55–60 ◦C. TLC
showed that the reaction was complete with major presence of the methyl ester inter-
mediate. Water was added, followed by 30% NaOH solution (2.61 g, 0.0195 moles) and
the mixture was heated at 60 ◦C for 2 h. TLC showed only the spot of the desired 2-
hydroxy 2-methyl-3-(4-trifluoromethylphenylthio) propionic acid (24). To a solution of 24
(1.36 g, 0.0593 moles) in 7 mL of anhydrous toluene was added acetic anhydride (0.601 mL,
0.00623 moles) and the resulting solution was heated at 100 ◦C for 5 h. After cooling to room
temperature, the solution was washed twice with 2 mL of water, and the combined organic
phases were dried and removed under reduced pressure. A dense oil was obtained, which
solidified spontaneously (25). To a solution of the acetoxy derivative (25) (0.4 g, 0.00146
moles) in 20 mL of anhydrous toluene at rt was added 0.127 mL (0.00148 moles) of thionyl
chloride, and the mixture was heated at 85–90 ◦C for 3–4 h. The solvent was completely
evaporated under reduced pressure. The product was obtained as an oil which was used
as is in the successive reaction. To a solution of the acid chloride (0.21g, 0.00072 moles) in
1.2 mL of anhydrous toluene was added 0.09 g (0.00072 moles) of DMAP, maintaining the
solution at room temperature; the suspension was allowed to react for 10 min, then 0.115 g
(0.00062 moles) of the corresponding 4-amino-benzonitrile derivative (2, 26) dissolved
in toluene was added and the mixture was heated at 75–80 ◦C for 8–10 h following the
disappearance of the amine by TLC (eluent: ethyl acetate/toluene 75/25). After cooling to
room temperature, the solution was diluted with toluene and treated with a 5% solution of
HCl, separated, and washed with 5% bicarbonate solution. The organic phase was cured
and evaporated under reduced pressure. Crude propionamide derivatives (48 and 49) were
obtained in quantitative yield [21].
2-Methyl-L-(4-nitro-2-(trifluoromethyl) phenylamino)-L-oxo-3-(4-(trifluoromethyl) phenylthio)
propan-2-yl acetate (27), yield 30%, 1H-NMR (CDCl3) δ 9.10 (s, 1H, NH), 8.62 (d, J = 9 Hz, 1H,
ArH), 8.54 (d, J = 2.5 Hz, 1H, ArH), 8.40 (dd, J = 3, 9 Hz, 1H, ArH), 7.45 (m, 4H, ArH), 4.07
(d, J = 14.5 Hz, 1H, CH2), 3.75 (d, J = 14 Hz, 1H, CH2), 1.99 (s, 3H, CH3), 1.89 (s, 3H, CH3);
19F-NMR (CDCl3) δ −61.29, −62.78; 13 C-NMR (CDCl3) δ 169.90 (C=O), 168.21 (C=O),
143.05 (ArC), 140.03 (ArC), 139.45 (ArC), 130.22 (ArCH), 128.90 (q, 2JC-F = 32.6 Hz, ArC),
128.49 (ArCH), 125.65 (q, 3JC-F = 3.8 Hz, ArCH), 123.79 (q, 1JC-F = 270.6 Hz, CF3), 123.03 (q,
1JC-F = 272.1 Hz, CF3), 122.34 (q, 3JC-F = 6.3 Hz, ArCH) 121.93, 121.89 (ArCH), 118.82 (q,
2JC-F = 31.3 Hz, ArC), 84.34 (COAc), 39.06 (CH2), 22.94 (CH3), 21.14 (CH3). MS (ES+) m/z:
511.1 [M + H]+, 533.1 [M + Na]+. Reverse-phase HPLC, eluting with H2O/CH3CN from
90/10 to 0/100 in 30 min; flow = 1 mL/min, tR = 25.50 min 97.3%.
2-Methyl-L-(4-nitro-3-(trifluoromethyl) phenylamino)-L-oxo-3-(4-(trifluoromethyl) phenylthio)
propan-2-yl acetate (28), yield 84%, 1H-NMR (CDCl3) δ 1.90 (s, 3H), 2.10 (s, 3H), 3.77 (d, J
= 14 Hz, 1H), 4.04 (d, J = 14 Hz, 1H), 7.44 (d, J = 8.5 Hz, 2H), 7.48 (d, J = 8.5 Hz, 2H), 7.88
(d, J = 2 Hz, 1H), 7.92 (dd, J = 2, 8.5 Hz, 1H), 7.97 (d, J = 9 Hz, 1H), 8.40 (s, 1H); 19F-NMR
(CDCl3) δ −62.80, −60.14; 13C-NMR (CDCl3) δ 169.84 (C=O), 168.59 (C=O), 144.75 (ArC),
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139.59 (ArC), 129.53 (ArCH), 129.11 (q, 2JC-F = 31.5 Hz, ArC), 126.95 (ArCH), 125.75 (q,
3JC-F = 3.8 Hz, ArCH), 124.84 (q, 1JC-F = 270.6 Hz, CF3), 123.43 (q, 1JC-F = 271.2 Hz, CF3),
122.56 (ArCH) 118.51 (ArCH), 118.50 (q, 2JC-F = 30.4 Hz, ArC), 83.89 (COAc), 60.39 (CH2),
22.95 (CH3), 21.69 (CH3). MS (ES+) m/z: 511.1 [M + H]+, 533.1 [M + Na]+. Reverse-phase
HPLC, eluting with H2O/CH3CN from 90/10 to 0/100 in 30 min; flow = 1 mL/min, tR =
24.40 min 96.31%.
2-Methyl-L-(4-nitro-2-(trifluoromethyl) phenylamino)- L-oxo-3-(4-(trifluoromethyl) phenylsulfinyl)
propan-2-yl acetate (29), yield 69%, 1H-NMR (CDCl3) δ [9.10 (s), 9.26 (s), 1H, NH], [8.73 (s),
8.75 (s), 1H, ArH], [8.57 (d, J = 2.5 Hz), 8.61 (d, J = 2.5 Hz), 1H, ArH], [8.47 (dd, J = 2.5,
9.5 Hz), 8.51 (dd, J = 2.5, 9.5 Hz), 1H, ArH), 7.81 (m, 4H, ArH), [3.62 (d, J = 14 Hz), 3.82 (s),
3.98 (d, J = 14 Hz), 2H, CH2], [2.25 (s), 2.36 (s), 3H, CH3], [1.93 (s), 1.96 (s), 3H, CH3]; 19F-
NMR (CDCl3) δ −61.29, −62.92; 13 C-NMR (CDCl3) δ 168.98 (C=O), 168.88 (C=O), 147.83
(ArC), (143.32, 142.47, ArC), (140.30, 139.97, ArC), 133.44 (m, ArC), 128.52 (ArCH), 126.47
(m, ArCH), 125.84 (q, 1JC-F = 263.4 Hz, CF3), [124.49, 124.43, ArCH], [123.13, 123.00, ArCH],
[122.54 (q, 3JC-F = 5 Hz), 122.40 (q, 3JC-F = 6.3 Hz), ArCH], 121.02 (q, 1JC-F = 226.9 Hz, CF3),
(82.06, 81.37, COCH3), (62.65, 61.75, CH2), (24.34, 23.98, CH3), (21.64, 21.61, CH3). MS (ES+)
m/z: 527.1 [M + H]+, 549.1 [M + Na]+. Reverse-phase HPLC, eluting with H2O/CH3CN
from 90/10 to 0/100 in 30 min; flow = 1 mL/min, tR = 22.54 min 98.81%.
2-Hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-3-(4-(trifluoromethyl) phenylsulfinyl)
propanamide (30), yield 59%, 1H-NMR (CDCl3) δ 9.47 (s, 1H, NH), 8.26 (d, J = 1.5 Hz, 1H,
ArH), 8.06 (m, 2H, ArH), 7.89 (d, J = 8.5 Hz, 2H, ArH), 7.83 (d, J = 8 Hz, 2H, ArH), 5.89
(s, 1H, OH), 3.61 (d, J = 13 Hz, 1H, CH2), 3.08 (d, J = 13 Hz, 1H, CH2), 1.62 (s, 3H, CH3);
19F-NMR (CDCl3) δ−60.10, −63.02; 13C-NMR (CDCl3) δ 173.26 (C=O), 149.51 (ArC), 145.87
(ArC), 141.21 (ArC), 137.77 (m, ArC), 126.84 (q, 3JC-F = 3.4 Hz, ArCH), 124.64 (ArCH), 124.35
(ArC), 124.24 (ArCH), 122.59 (ArC), 122.32 (ArCH), 120.64 (m, ArC), 118.50 (q, 3JC-F = 5 Hz,
ArCH), 76.80 (COH), 62.25 (CH2), 28.25 (CH3). MS (ES+) m/z: 485.1 [M + H]+, 507.1 [M +
Na]+. Reverse-phase HPLC, eluting with H2O/CH3CN from 90/10 to 0/100 in 30 min;
flow = 1 mL/min, tR = 18.95 min 96.76%.
2-Methyl-L-(4-nitro-2-(trifluoromethyl) phenylamino)-L-oxo-3-(4-(trifluoromethyl) phenylsulfonyl)
propan-2-yl acetate (31), yield 83%, 1H-NMR (CDCl3) δ 9.22 (s, 1H, NH), 8.71 (d, J = 9.5 Hz,
1H, ArH), 8.60 (d, J = 2.5 Hz, 1H, ArH), 8.49 (dd, J = 2.5, 9 Hz, 1H, ArH), 8.06 (d, J = 8 Hz,
2H, ArH), 7.84 (d, J = 8.5 Hz, 2H, ArH), 4.41 (d, J = 14.5 Hz, 1H, CH2), 4.07 (d, J = 14.5
Hz, 1H, CH2), 2.26 (s, 3H, CH3), 1.90 (s, 3H, CH3); 19F-NMR (CDCl3) δ −63.31, −61.29; 13
C-NMR (CDCl3) δ 169.05 (C=O), 168.72 (C=O), 143.39 (ArC), 143.02 (ArC), 140.14 (ArC),
136.06 (m, ArC), 128.75 (ArCH), 128.54 (ArCH), 126.57 (q, 3JC-F = 3.8 Hz, ArCH), 124.07
(m, 2CF3), 122.82 (ArCH), 122.47 (q, 3JC-F = 5 Hz, ArCH), 121.09 (m, ArC), 80.16 (COAc),
57.74 (CH2), 24.36 (CH3), 21.72 (CH3). MS (ES+) m/z: 543.1 [M + H]+, 565.1 [M + Na]+
Reverse-phase HPLC, eluting with H2O/CH3CN from 90/10 to 0/100 in 30 min; flow =
1 mL/min, tR = 24.08 min 96.52%.
3.2. Cell Growth Inhibition Viability Assay
All bicalutamide derivatives were screened for their antiproliferative activity using the
Oncotest monolayer assay against four human prostate cancer cell lines (22Rv1, DU-145,
LNCaP, and VCap). Bicalutamide and enzalutamide were used as positive controls.
A modified propidium iodide (PI)-based monolayer assay was used to assess the
anticancer activity of the compounds. Briefly, cells were harvested from exponential phase
cultures, counted, and plated in 96-well flat-bottom microtiter plates at a cell density
of 8000–12,000 cells/well. After a 24 h recovery period to allow the cells to resume
exponential growth, 10 mL of culture medium (six control wells/plate) or culture medium
with test compound was added. The compounds were applied in half-log increments at
10 concentrations in triplicate. After a total treatment period of 96 h, cells were washed
with 200 mL PBS to remove dead cells and debris. Then, 200 mL of a solution containing
7 mg/mL propidium iodide (PI) and 0.1% (v/v) Triton X-100 was added. After an incubation
period of 1–2 h at room temperature, fluorescence (FU) was measured using the EnSpire
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Multimode Plate Reader (excitation l = 530 nm, emission l = 620 nm) to quantify the amount
of attached viable cells. IC50 values were calculated by four-parameter nonlinear curve fit
using Oncotest Warehouse Software. For calculation of mean IC50 values, the geometric
mean was used [23].
3.3. Docking Studies
The X-ray crystal structure of the human androgen receptor ligand-binding domain
hAR-LBD was downloaded from the Protein Data Bank (PDB code; 3RLJ) [24] and prepared
for docking using the MOE (Molecular Operating Environment) [25] protein preparation
tools. The chemical structures of our compounds were constructed, rendered, and mini-
mized with the MMFF94x force-field in MOE. The docking simulations were performed
using the Glide SP within Maestro software using the default settings (Glide, version 9.5,
Schrodinger) [26]. The docking output database was saved as a mol2 file, and the visual
inspection of the docking modes was performed in MOE.
4. Conclusions
Fifteen bicalutamide derivatives were prepared and their antiproliferative activity was
evaluated in vitro against four different human prostate cancer cell lines (22Rv1, DU-145,
LNCaP, and VCap). These modifications offer an insight into the SAR of various propio-
nanilide analogues. Bicalutamide and enzalutamide were used as positive controls. The
results summarized in Tables 1–4 indicated that seven compounds, sulfide (12), deshy-
droxy (16, 17), sulfone (21), and acetylated (27) derivatives, have better antiproliferative
activity than the positive controls, bicalutamide (IC50 = 45.20–51.61 µM) and enzalutamide
(IC50 = 11.47–53.04 µM). The deshydroxy analogue (16) was the most active compound
with IC50 = 6.59–10.86 µM, followed by the acetylated derivative (27) with IC50 = 4.69–15.03
µM across the four prostate cancer cell lines. Molecular modeling was used to find a
plausible explanation of the drop in activity upon oxidation of the sulfide analogue (16)
into sulfone counterpart (21). The dose response curves of compounds (16, 17) and their
oxidized analogues (21, 22) are represented in Figure 3. Retention and enhancement of
bicalutamide antiproliferative activity were observed in some compounds. Displaying
antiproliferative activity in the 22Rv1 and DU-145 cell lines suggests that other antiprolifer-
ative mechanisms could be involved. This possible off-target effect was noticed as well in
the parent bicalutamide, which showed similar IC50 values across the four cell lines. These
findings may serve as a useful starting point for developing novel AR modulators.
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